TipRanks
Teva Pharmaceutical Industries Limited (TEVA)
NYSE:TEVA
US Market
TEVA
Teva
RESEARCH TOOLSreports
Want to see TEVA full AI Analyst Report?

Teva (TEVA) Stock Forecast & Price Target

46 Followers
See the Price Targets and Ratings of:

TEVA Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Teva
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TEVA Stock 12 Month Forecast

Average Price Target

$48.41
▲(27.06% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Teva in the last 3 months. The average price target is $48.41 with a high forecast of $55.00 and a low forecast of $43.00. The average price target represents a 27.06% change from the last price of $38.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","36":"$36","55":"$55","26.5":"$26.5","45.5":"$45.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54.9999999788008,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.41134131680224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.99999998342608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,26.5,36,45.5,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.31,40.51692307529237,41.72384615058474,42.93076922587711,44.13769230116948,45.344615376461846,46.55153845175422,47.758461527046585,48.96538460233896,50.17230767763132,51.3792307529237,52.58615382821606,53.793076903508435,{"y":54.9999999788008,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.31,40.01010317821556,40.710206356431115,41.41030953464667,42.11041271286223,42.810515891077785,43.51061906929334,44.2107222475089,44.91082542572446,45.61092860394002,46.311031782155574,47.01113496037113,47.71123813858669,{"y":48.41134131680224,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.31,39.59384615257124,39.877692305142475,40.16153845771371,40.44538461028495,40.72923076285618,41.01307691542742,41.29692306799866,41.5807692205699,41.864615373141135,42.14846152571237,42.43230767828361,42.71615383085484,{"y":42.99999998342608,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.5,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":28.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.31,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$55.00Average Price Target$48.41Lowest Price Target$43.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on TEVA
Glen Santangelo
Barclays
Barclays
$47
Buy
23.36%
Upside
Reiterated
10/15/26
Teva (TEVA) Receives a Buy from Barclays
Scotiabank Analyst forecast on TEVA
Louise Chen
Scotiabank
Scotiabank
$47
Buy
23.36%
Upside
Reiterated
10/12/26
Scotiabank Sticks to Its Buy Rating for Teva (TEVA)
Goldman Sachs Analyst forecast on TEVA
Salveen Richter
Goldman Sachs
Goldman Sachs
$50
Buy
31.23%
Upside
Reiterated
10/12/26
Salveen Richter Reiterates Buy on Teva, Sets $50 12-Month Target Backed by EV/EBITDA Valuation Ahead of Q3 Earnings
Leader Capital Markets Analyst forecast on TEVA
Sabina Levi
Leader Capital Markets
Leader Capital Markets
$49.7
Buy
30.45%
Upside
Reiterated
10/12/26
Leader Capital Markets Reaffirms Their Buy Rating on Teva (TEVA)
J.P. Morgan Analyst forecast on TEVA
Chris Schott
J.P. Morgan
J.P. Morgan
$40→$50
Buy
31.23%
Upside
Reiterated
10/11/26
Teva price target raised to $50 from $40 at JPMorganTeva price target raised to $50 from $40 at JPMorgan
Bank of America Securities Analyst forecast on TEVA
Jason Gerberry
Bank of America Securities
Bank of America Securities
$43
Buy
12.86%
Upside
Reiterated
10/09/26
Bank of America Securities Sticks to Its Buy Rating for Teva (TEVA)
Piper Sandler Analyst forecast on TEVA
David Amsellem
Piper Sandler
Piper Sandler
$44
Buy
15.49%
Upside
Reiterated
10/01/26
Piper Sandler Sticks to Its Buy Rating for Teva (TEVA)
TD Cowen Analyst forecast on TEVA
Joseph Thome
TD Cowen
TD Cowen
$55
Buy
44.36%
Upside
Initiated
10/01/26
Teva initiated with a Buy at TD CowenTeva initiated with a Buy at TD Cowen
Oppenheimer Analyst forecast on TEVA
Les Sulewski
Oppenheimer
Oppenheimer
$50
Buy
31.23%
Upside
Initiated
09/23/26
Teva initiated with an Outperform at OppenheimerTeva initiated with an Outperform at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on TEVA
Glen Santangelo
Barclays
Barclays
$47
Buy
23.36%
Upside
Reiterated
10/15/26
Teva (TEVA) Receives a Buy from Barclays
Scotiabank Analyst forecast on TEVA
Louise Chen
Scotiabank
Scotiabank
$47
Buy
23.36%
Upside
Reiterated
10/12/26
Scotiabank Sticks to Its Buy Rating for Teva (TEVA)
Goldman Sachs Analyst forecast on TEVA
Salveen Richter
Goldman Sachs
Goldman Sachs
$50
Buy
31.23%
Upside
Reiterated
10/12/26
Salveen Richter Reiterates Buy on Teva, Sets $50 12-Month Target Backed by EV/EBITDA Valuation Ahead of Q3 Earnings
Leader Capital Markets Analyst forecast on TEVA
Sabina Levi
Leader Capital Markets
Leader Capital Markets
$49.7
Buy
30.45%
Upside
Reiterated
10/12/26
Leader Capital Markets Reaffirms Their Buy Rating on Teva (TEVA)
J.P. Morgan Analyst forecast on TEVA
Chris Schott
J.P. Morgan
J.P. Morgan
$40→$50
Buy
31.23%
Upside
Reiterated
10/11/26
Teva price target raised to $50 from $40 at JPMorganTeva price target raised to $50 from $40 at JPMorgan
Bank of America Securities Analyst forecast on TEVA
Jason Gerberry
Bank of America Securities
Bank of America Securities
$43
Buy
12.86%
Upside
Reiterated
10/09/26
Bank of America Securities Sticks to Its Buy Rating for Teva (TEVA)
Piper Sandler Analyst forecast on TEVA
David Amsellem
Piper Sandler
Piper Sandler
$44
Buy
15.49%
Upside
Reiterated
10/01/26
Piper Sandler Sticks to Its Buy Rating for Teva (TEVA)
TD Cowen Analyst forecast on TEVA
Joseph Thome
TD Cowen
TD Cowen
$55
Buy
44.36%
Upside
Initiated
10/01/26
Teva initiated with a Buy at TD CowenTeva initiated with a Buy at TD Cowen
Oppenheimer Analyst forecast on TEVA
Les Sulewski
Oppenheimer
Oppenheimer
$50
Buy
31.23%
Upside
Initiated
09/23/26
Teva initiated with an Outperform at OppenheimerTeva initiated with an Outperform at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Teva

3 Months
Chris SchottJ.P. Morgan
Success Rate
2/2 ratings generated profit
100%
Average Return
+6.80%
Copying Chris Schott's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.80% per trade.
1 Year
Sabina LeviLeader Capital Markets
Success Rate
7/7 ratings generated profit
100%
Average Return
+54.03%
Copying Sabina Levi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +54.03% per trade.
2 Years
Sabina LeviLeader Capital Markets
Success Rate
7/7 ratings generated profit
100%
Average Return
+83.91%
Copying Sabina Levi's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +83.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TEVA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
2
1
1
4
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
1
1
4
14
In the current month, TEVA has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TEVA average Analyst price target in the past 3 months is 48.41.
Each month's total comprises the sum of three months' worth of ratings.

TEVA Financial Forecast

TEVA Earnings Forecast

Next quarter’s earnings estimate for TEVA is $0.72 with a range of $0.60 to $0.89. The previous quarter’s EPS was $0.02. TEVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year TEVA has Performed in-line its overall industry.
Next quarter’s earnings estimate for TEVA is $0.72 with a range of $0.60 to $0.89. The previous quarter’s EPS was $0.02. TEVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year TEVA has Performed in-line its overall industry.

TEVA Sales Forecast

Next quarter’s sales forecast for TEVA is $4.21B with a range of $4.01B to $4.33B. The previous quarter’s sales results were $3.98B. TEVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year TEVA has Performed in-line its overall industry.
Next quarter’s sales forecast for TEVA is $4.21B with a range of $4.01B to $4.33B. The previous quarter’s sales results were $3.98B. TEVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year TEVA has Performed in-line its overall industry.

TEVA Stock Forecast FAQ

What is TEVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Teva Pharmaceutical Industries Limited’s 12-month average price target is 48.41.
    What is TEVA’s upside potential, based on the analysts’ average price target?
    Teva Pharmaceutical Industries Limited has 27.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TEVA a Buy, Sell or Hold?
          Teva Pharmaceutical Industries Limited has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Teva Pharmaceutical Industries Limited’s price target?
            The average price target for Teva Pharmaceutical Industries Limited is 48.41. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $55.00 ,the lowest forecast is $43.00. The average price target represents 27.06% Increase from the current price of $38.1.
              What do analysts say about Teva Pharmaceutical Industries Limited?
              Teva Pharmaceutical Industries Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of TEVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.